XML 42 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
2. Revenue
6 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue

The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”). In accordance with ASC Topic 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.

 

Nature of Products and Services

 

We generate revenues from the following sources: (1) Benchtop Laboratory Equipment, (2) Catalyst Research Instruments and (3) Royalties.

 

The following table summarizes the Company’s disaggregation of revenues for the three and six months ended December 31, 2019 and 2018.

 

    Benchtop Laboratory Equipment     Catalyst Research Instruments    

Bioprocessing

Systems

    Consolidated  
Three Months Ended December 31, 2019:                        
Revenues   $ 1,943,400     $ 39,500     $ 289,400     $ 2,272,300  
Foreign Sales     855,800       10,200       289,400       1,155,400  
                                 
Three Months Ended December 31, 2018:                                
Revenues   $ 1,803,100     $ 227,200     $ 132,900     $ 2,163,200  
Foreign Sales     743,600       222,900       128,600       1,095,100  

 

    Benchtop Laboratory Equipment     Catalyst Research Instruments    

Bioprocessing

Systems

    Consolidated  
Six Months Ended December 31, 2019:                        
Revenues   $ 3,519,600     $ 178,200     $ 578,700     $ 4,276,500  
Foreign Sales     1,253,400       81,900       578,700       1,914,000  

 

Six Months Ended December 31, 2018:                        
Revenues   $ 3,495,100     $ 444,600     $ 262,100     $ 4,201,800  
Foreign Sales     1,379,300       365,200       257,100       2,001,600  

 

Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment from its stock to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. The standard warranty is typically comprised of one to two years of parts and labor and is deemed immaterial.

 

Catalyst Research Instrument sales are comprised primarily of large instruments which begin with a standard model and then are customized to a customer’s specifications. The sales cycle can be quite long, typically ranging from one to three months, from the time an order is received to the time the instrument is shipped to the customer. Payment terms vary from customer to customer and can include advance payments which are recorded as contract liabilities. Some contracts call for training and installation, which is considered ancillary and not a material part of the contract. Due to the size and nature of the instruments, the Company subjects the instruments to an extensive factory acceptance testing process prior to shipment to ensure that they are fully operational once they reach the customer’s site. Normally, the Company warrantees its instruments for a period of twelve months for parts and labor which normally consists of replacement of small components or software support. Catalyst research instruments are never returned for repairs.

 

Royalty revenues pertain to royalties earned by the Company, which are paid on a calendar year basis, under a licensing agreement from a single licensee and its sublicenses. The Company is then obligated to pay 50% of all royalties received to the entity that licenses the intellectual property to the Company. During the year, the Company’s management uses its best judgement to estimate the royalty revenues earned during the period.

 

The Company determines revenue recognition through the following steps:

 

  Identification of the contract, or contracts, with a customer
  Identification of the performance obligations in the contract
  Determination of the transaction price
  Allocation of the transaction price to the performance obligations in the contract
  Recognition of revenue when, or as, a performance obligation is satisfied

 

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC Topic 606: 1) all revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.